DINUTUXIMAB
Dinutuximab is a monoclonal antibody against GD2 on neuroblastoma cells, mediating immunemediated cytotoxicity. Used in highrisk pediatric neuroblastoma. Side effects include severe neuropathic pain, hypotension, capillary leak, infections, and infusionrelated reactions. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
DINUTUXIMAB displays a highdimensional biochemical interaction profile, integrating catalyticdomain modulation, multiaxis signalling interference, mitochondrialnetwork recalibration, ionflux redistribution, membranepotential rebalancing, cytoskeletal remodelling, redoxequilibrium restructuring and transcriptionfactor pathway reprogramming. Its molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotidebinding pockets, redoxbuffer centres and polymeric scaffolding complexes, enabling wideband influence across metabolic, genomic, structural and electrophysiological layers.
At the signalling level, DINUTUXIMAB may reconfigure phosphorylation landscapes spanning ERK/MAPK/JNK/p38 and PI3KAKT axes, modulate Gprotein coupling states, reorganise Ca²⁺ microdomain geometry, adjust IP/DAG cascade topology, and recalibrate cAMPPKA amplitude distributions. Mitochondrial effects can include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, membranepotential polarity shifts and bidirectional stresssignal integration between ER and mitochondrial compartments.
Advanced
- Kinomescale catalyticcascade interference mapping
- Highresolution docking & conformationaltransition simulations
- UPR/ERstress, mitophagy & autophagicflux network analysis
- Full multiomics integration (RNAseq, proteomics, phosphoproteomics, metabolomics)
- Cytoskeletal mechanics & polymerturnover/forcedistribution modelling
- Cellfate pathway simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
- AIdriven SAR/QSAR pipelines for compoundperformance prediction
Toxicodynamics & Hazard Spectrum
- Rapid ROS escalation & antioxidantbuffer saturation
- Mitochondrial fragmentation or ETCaxis suppression
- Severe Na⁺/K⁺/Ca²⁺ ionic-flux destabilisation
- Cytoskeletal depolymerisation & membrane-integrity loss
- Hyperactivation of NF-κB, STAT & IRF inflammatory regulators
- Induction of multiaxis programmed-cell-death pathways
- Epigenetic drift including methylation/acetylation imbalance
For expert laboratory research only not intended for biological or therapeutic exposure.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | Protein |
|---|---|
| Molecular Weight | 255.27 g/mol |
| CAS Number | 74103-06-3 |
| Storage Condition | Store at 28°C |
| Solubility | Soluble in water |
| Purity | Purity information is available upon request (COA). |
| Synonym | ketorolac; 74103-06-3; Ketorolaco; Ketorolacum; (+-)-Ketorolac |
| IUPAC/Chemical Name | AntiGD2 monoclonal antibody |
| InChl Key | Unavailable |
| InChl Code | Unavailable |
| References | PubChem; ChemBL; FDA; |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
